RxDoctor Payments Data

Justin Grissom, DO

Family Medicine · Conroe, TXNPI 1063774842

Payments from drug & device makers

$460in general payments, 2019–2025

Across 29 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$67
  • Novo Nordisk$63
  • AstraZeneca$49
  • Amgen$32
  • Sanofi Pasteur Inc.$29
  • Amarin Pharma, Inc.$28
  • plus $191 from 11 others

What the payments were for

  • Food & beverage$460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$460 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$107,235
Medicare patients
357
Services billed
4,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$126,759
OzempicSemaglutide81$117,984
JardianceEmpagliflozin53$67,413
TrulicityDulaglutide42$54,964
MounjaroTirzepatide42$50,871
FarxigaDapagliflozin Propanediol31$50,847
JanuviaSitagliptin Phosphate44$48,632
XareltoRivaroxaban46$45,563
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$42,134
Tresiba Flextouch U-200Insulin Degludec16$39,772
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$22,705
MyrbetriqMirabegron12$10,293
SymbicortBudesonide/Formoterol Fumarate26$9,368
LinzessLinaclotide13$8,815
Tresiba Flextouch U-100Insulin Degludec17$8,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$126,759122 claims
Novo NordiskOzempic$63$117,98481 claims
Lilly USA, LLCTrulicity, Mounjaro$11$105,83584 claims
AstraZenecaFarxiga, Symbicort$49$60,21457 claims
GSKTrelegy Ellipta, Anoro Ellipta$18$49,33569 claims
Johnson & JohnsonXarelto$67$45,56346 claims
Astellas Pharma US IncMyrbetriq$24$10,29312 claims
AbbVieLinzess$28$8,81513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →